Abstract
To show, as a model system, that mycobacteria can express heterologous luciferase genes and that bioluminescence can be a rapid method of measuring antimycobacterial activity, a bioluminescent form of Mycobacterium smegmatis was made by transformation with a Mycobacterium-Escherichia coli shuttle vector containing the luxAB genes from Vibrio harveyi. The antimycobacterial effects of antibiotics and biocides could be assayed in real time by using bioluminescent M. smegmatis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chaisson R. E., Slutkin G. Tuberculosis and human immunodeficiency virus infection. J Infect Dis. 1989 Jan;159(1):96–100. doi: 10.1093/infdis/159.1.96. [DOI] [PubMed] [Google Scholar]
- Collins F. M. Kinetics of the tuberculocidal response by alkaline glutaraldehyde in solution and on an inert surface. J Appl Bacteriol. 1986 Jul;61(1):87–93. doi: 10.1111/j.1365-2672.1986.tb03762.x. [DOI] [PubMed] [Google Scholar]
- Davis D., Bonekat H. W., Andrews D., Shigeoka J. W. Disinfection of the flexible fibreoptic bronchoscope against Mycobacterium tuberculosis and M gordonae. Thorax. 1984 Oct;39(10):785–788. doi: 10.1136/thx.39.10.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dickinson J. M., Mitchison D. A. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183–193. doi: 10.1016/0041-3879(87)90054-7. [DOI] [PubMed] [Google Scholar]
- Hill P. J., Swift S., Stewart G. S. PCR based gene engineering of the Vibrio harveyi lux operon and the Escherichia coli trp operon provides for biochemically functional native and fused gene products. Mol Gen Genet. 1991 Apr;226(1-2):41–48. doi: 10.1007/BF00273585. [DOI] [PubMed] [Google Scholar]
- Khor M., Lowrie D. B., Mitchison D. A. Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro. Br J Exp Pathol. 1986 Oct;67(5):707–717. [PMC free article] [PubMed] [Google Scholar]
- Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991 Mar;72(1):1–6. doi: 10.1016/0041-3879(91)90017-m. [DOI] [PubMed] [Google Scholar]
- Russell A. D., Ahonkhai I., Rogers D. T. Microbiological applications of the inactivation of antibiotics and other antimicrobial agents. J Appl Bacteriol. 1979 Apr;46(2):207–245. doi: 10.1111/j.1365-2672.1979.tb00818.x. [DOI] [PubMed] [Google Scholar]
- Snapper S. B., Melton R. E., Mustafa S., Kieser T., Jacobs W. R., Jr Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol. 1990 Nov;4(11):1911–1919. doi: 10.1111/j.1365-2958.1990.tb02040.x. [DOI] [PubMed] [Google Scholar]
- Stewart G. S. In vivo bioluminescence: new potentials for microbiology. Lett Appl Microbiol. 1990 Jan;10(1):1–8. doi: 10.1111/j.1472-765x.1990.tb00082.x. [DOI] [PubMed] [Google Scholar]
- Stover C. K., de la Cruz V. F., Fuerst T. R., Burlein J. E., Benson L. A., Bennett L. T., Bansal G. P., Young J. F., Lee M. H., Hatfull G. F. New use of BCG for recombinant vaccines. Nature. 1991 Jun 6;351(6326):456–460. doi: 10.1038/351456a0. [DOI] [PubMed] [Google Scholar]
- Watson J. M., Gill O. N. HIV infection and tuberculosis. BMJ. 1990 Jan 13;300(6717):63–65. doi: 10.1136/bmj.300.6717.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Watt B. Drug resistant tuberculosis. BMJ. 1992 Oct 3;305(6857):831–832. doi: 10.1136/bmj.305.6857.831-c. [DOI] [PMC free article] [PubMed] [Google Scholar]